Cargando…

Impact of different guidewires on the implantation depth using the largest self-expandable TAVI device

BACKGROUND: The deployment process of the largest self-expandable device (STHV-34) during transcatheter aortic valve implantation (TAVI) might be challenging due to stabilization issues. Whether the use of different TAVI-guidewires impact the procedural success and outcome is not well-known. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales: Veulemans, Verena, Wilde, Nihal, Wienemann, Hendrik, Adrichem, Rik, Hokken, Thijmen W., Al-Kassou, Baravan, Shamekhi, Jasmin, Mauri, Victor, Maier, Oliver, Jung, Christian, Horn, Patrick, Adam, Matti, Nickenig, Georg, Baldus, Stephan, Van Mieghem, Nicolas M., Kelm, Malte, Sedaghat, Alexander, Zeus, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849574/
https://www.ncbi.nlm.nih.gov/pubmed/36684595
http://dx.doi.org/10.3389/fcvm.2022.1064916
Descripción
Sumario:BACKGROUND: The deployment process of the largest self-expandable device (STHV-34) during transcatheter aortic valve implantation (TAVI) might be challenging due to stabilization issues. Whether the use of different TAVI-guidewires impact the procedural success and outcome is not well-known. Therefore, we sought to evaluate the impact of non-Lunderquist (NLu) vs. the Lunderquist (Lu) guidewires during TAVI using the STHV-34 on the procedural and 30-day outcomes. METHODS: The primary study endpoint was defined as the final implantation depth (ID) depending on the selected guidewire strategy. Key secondary endpoints included VARC-3-defined complications. RESULTS: The study cohort included 398 patients of four tertiary care institutions, of whom 79.6% (317/398) had undergone TAVI using NLu and 20.4% (81/398) using Lu guidewires. Baseline characteristics did not substantially differ between NLu and Lu patients. The average ID was higher in the Lu cohort (NLu vs. Lu: −5.2 [−7.0–(−3.5)] vs. −4.5 [−6.0–(−3.0)]; p = 0.022(*)). The optimal ID was reached in 45.0% of patients according to former and only in 20.1% according to nowadays best practice recommendations. There was no impact of the guidewire use on the 30-day outcomes, including conduction disturbances and pacemaker need (NLu vs. Lu: 15.1 vs. 18.5%; p = 0.706). CONCLUSION: The use of the Lunderquist(TM) guidewire was associated with a higher ID during TAVI with the STHV-34 without measurable benefits in the 30-day course concerning conduction disturbances and associated pacemaker need. Whether using different guidewires might impact the outcome in challenging anatomies should be further investigated in randomized studies under standardized conditions.